Genetic and Phenotypic Landscape of Peripartum Cardiomyopathy

Supplemental Digital Content is available in the text. Background: Peripartum cardiomyopathy (PPCM) occurs in ≈1:2000 deliveries in the United States and worldwide. The genetic underpinnings of PPCM remain poorly defined. Approximately 10% of women with PPCM harbor truncating variants in TTN (TTNtvs). Whether mutations in other genes can predispose to PPCM is not known. It is also not known if the presence of TTNtvs predicts clinical presentation or outcomes. Nor is it known if the prevalence of TTNtvs differs in women with PPCM and preeclampsia, the strongest risk factor for PPCM. Methods: Women with PPCM were retrospectively identified from several US and international academic centers, and clinical information and DNA samples were acquired. Next-generation sequencing was performed on 67 genes, including TTN, and evaluated for burden of truncating and missense variants. The impact of TTNtvs on the severity of clinical presentation, and on clinical outcomes, was evaluated. Results: Four hundred sixty-nine women met inclusion criteria. Of the women with PPCM, 10.4% bore TTNtvs (odds ratio=9.4 compared with 1.2% in the reference population; Bonferroni-corrected P [P*]=1.2×10–46). We additionally identified overrepresentation of truncating variants in FLNC (odds ratio=24.8, P*=7.0×10–8), DSP (odds ratio=14.9, P*=1.0×10–8), and BAG3 (odds ratio=53.1, P*=0.02), genes not previously associated with PPCM. This profile is highly similar to that found in nonischemic dilated cardiomyopathy. Women with TTNtvs had lower left ventricular ejection fraction on presentation than did women without TTNtvs (23.5% versus 29%, P=2.5×10–4), but did not differ significantly in timing of presentation after delivery, in prevalence of preeclampsia, or in rates of clinical recovery. Conclusions: This study provides the first extensive genetic and phenotypic landscape of PPCM and demonstrates that predisposition to heart failure is an important risk factor for PPCM. The work reveals a degree of genetic similarity between PPCM and dilated cardiomyopathy, suggesting that gene-specific therapeutic approaches being developed for dilated cardiomyopathy may also apply to PPCM, and that approaches to genetic testing in PPCM should mirror those taken in dilated cardiomyopathy. Last, the clarification of genotype/phenotype associations has important implications for genetic counseling.

[1]  G. Perrault.  Bureau , 2021, La boussole du confiné.

[2]  S. Priori,et al.  Desmoplakin Cardiomyopathy, a Fibrotic and Inflammatory Form of Cardiomyopathy Distinct From Typical Dilated or Arrhythmogenic Right Ventricular Cardiomyopathy , 2020, Circulation.

[3]  Angharad M Roberts,et al.  Reevaluating the Genetic Contribution of Monogenic Dilated Cardiomyopathy , 2020, Circulation.

[4]  S. Goland,et al.  Peripartum Cardiomyopathy: JACC State-of-the-Art Review. , 2020, Journal of the American College of Cardiology.

[5]  M. Elovitz,et al.  Importance of Early Diagnosis in Peripartum Cardiomyopathy. , 2019, Hypertension.

[6]  M. Link,et al.  2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy: Executive summary. , 2019, Heart rhythm.

[7]  J. Clayton-Smith,et al.  Functional and in-silico interrogation of rare genomic variants impacting RNA splicing for the diagnosis of genomic disorders , 2019, bioRxiv.

[8]  Raquel Yotti,et al.  Advances in the Genetic Basis and Pathogenesis of Sarcomere Cardiomyopathies. , 2019, Annual review of genomics and human genetics.

[9]  C. Perret,et al.  FLNC pathogenic variants in patients with cardiomyopathies: Prevalence and genotype‐phenotype correlations , 2019, Clinical genetics.

[10]  Brandon K. Fornwalt,et al.  Genomics-First Evaluation of Heart Disease Associated With Titin-Truncating Variants. , 2019, Circulation.

[11]  David G. Knowles,et al.  Predicting Splicing from Primary Sequence with Deep Learning , 2019, Cell.

[12]  D. Judge,et al.  Genetic evaluation of cardiomyopathy: a clinical practice resource of the American College of Medical Genetics and Genomics (ACMG) , 2018, Genetics in Medicine.

[13]  D. O’Regan,et al.  Genetic Etiology for Alcohol-Induced Cardiac Toxicity , 2018, Journal of the American College of Cardiology.

[14]  S. Cook,et al.  Role of titin in cardiomyopathy: from DNA variants to patient stratification , 2018, Nature Reviews Cardiology.

[15]  Kenneth L. Jones,et al.  Filamin C Truncation Mutations Are Associated With Arrhythmogenic Dilated Cardiomyopathy and Changes in the Cell–Cell Adhesion Structures , 2018, JACC. Clinical electrophysiology.

[16]  H. Aburatani,et al.  Genetic basis of cardiomyopathy and the genotypes involved in prognosis and left ventricular reverse remodeling , 2018, Scientific Reports.

[17]  C. Dauphin,et al.  Truncating mutations on myofibrillar myopathies causing genes as prevalent molecular explanations on patients with dilated cardiomyopathy , 2017, Clinical genetics.

[18]  Y. Pinto,et al.  Truncating titin mutations are associated with a mild and treatable form of dilated cardiomyopathy , 2017, European journal of heart failure.

[19]  M. Umesawa,et al.  Epidemiology of hypertensive disorders in pregnancy: prevalence, risk factors, predictors and prognosis , 2017, Hypertension Research.

[20]  L. Calò,et al.  Truncating FLNC Mutations Are Associated With High-Risk Dilated and Arrhythmogenic Cardiomyopathies. , 2016, Journal of the American College of Cardiology.

[21]  J. Seidman,et al.  Shared Genetic Predisposition in Peripartum and Dilated Cardiomyopathies. , 2016, The New England journal of medicine.

[22]  N. Bello,et al.  Molecular mechanisms of peripartum cardiomyopathy: A vascular/hormonal hypothesis. , 2015, Trends in cardiovascular medicine.

[23]  Tan Ru San,et al.  Integrated allelic, transcriptional, and phenomic dissection of the cardiac effects of titin truncations in health and disease , 2015, Science Translational Medicine.

[24]  N. Bello,et al.  The relationship between pre-eclampsia and peripartum cardiomyopathy: a systematic review and meta-analysis. , 2013, Journal of the American College of Cardiology.

[25]  S. Goland,et al.  Differences in clinical profile of African-American women with peripartum cardiomyopathy in the United States. , 2013, Journal of cardiac failure.

[26]  John Mitchell,et al.  Cardiac Angiogenic Imbalance Leads to Peri-partum Cardiomyopathy , 2012, Nature.

[27]  L. Mestroni,et al.  Truncations of titin causing dilated cardiomyopathy. , 2012, The New England journal of medicine.

[28]  H. Calkins,et al.  HRS/EHRA expert consensus statement on the state of genetic testing for the channelopathies and cardiomyopathies this document was developed as a partnership between the Heart Rhythm Society (HRS) and the European Heart Rhythm Association (EHRA). , 2011, Heart rhythm.

[29]  Deborah A Nickerson,et al.  Genome-wide studies of copy number variation and exome sequencing identify rare variants in BAG3 as a cause of dilated cardiomyopathy. , 2011, American journal of human genetics.

[30]  A. Keren,et al.  Genetic counselling and testing in cardiomyopathies: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. , 2010, European heart journal.

[31]  K. Sliwa,et al.  Current state of knowledge on aetiology, diagnosis, management, and therapy of peripartum cardiomyopathy: a position statement from the Heart Failure Association of the European Society of Cardiology Working Group on peripartum cardiomyopathy , 2010, European journal of heart failure.

[32]  Steven S. Khan,et al.  Incidence, mortality, and racial differences in peripartum cardiomyopathy. , 2007, The American journal of cardiology.

[33]  K. Sliwa,et al.  A Cathepsin D-Cleaved 16 kDa Form of Prolactin Mediates Postpartum Cardiomyopathy , 2007, Cell.

[34]  U. Elkayam,et al.  Peripartum Cardiomyopathy. , 2016, Circulation.